Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Lowered by StockNews.com

StockNews.com downgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY - Free Report) from a buy rating to a hold rating in a research note issued to investors on Friday morning.

Other analysts also recently issued research reports about the company. William Blair restated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 26th. Morgan Stanley increased their target price on shares of Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an "equal weight" rating in a report on Friday, February 14th. Royal Bank of Canada restated an "outperform" rating and set a $310.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 26th. JPMorgan Chase & Co. lifted their price objective on Alnylam Pharmaceuticals from $272.00 to $280.00 and gave the stock a "neutral" rating in a report on Tuesday, March 11th. Finally, HC Wainwright raised their price target on Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the stock a "buy" rating in a research report on Monday, February 24th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty have given a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $312.30.

Remove Ads

Alnylam Pharmaceuticals Stock Performance

ALNY traded up $7.36 on Friday, hitting $290.70. The company's stock had a trading volume of 1,767,764 shares, compared to its average volume of 806,052. The company's 50 day simple moving average is $257.16 and its 200-day simple moving average is $259.74. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $304.39. The firm has a market cap of $37.63 billion, a P/E ratio of -133.96 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Analysts forecast that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Insider Buying and Selling

In related news, CMO Pushkal Garg sold 1,548 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total value of $389,585.16. Following the sale, the chief marketing officer now owns 11,989 shares in the company, valued at approximately $3,017,271.63. The trade was a 11.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total transaction of $362,246.40. Following the completion of the transaction, the executive vice president now directly owns 12,881 shares of the company's stock, valued at $3,240,344.36. The trade was a 10.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 71,234 shares of company stock worth $19,958,097. Corporate insiders own 1.50% of the company's stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System grew its stake in Alnylam Pharmaceuticals by 2.6% in the fourth quarter. California State Teachers Retirement System now owns 196,362 shares of the biopharmaceutical company's stock valued at $46,206,000 after purchasing an additional 5,037 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its position in Alnylam Pharmaceuticals by 94.7% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 12,566 shares of the biopharmaceutical company's stock worth $2,957,000 after buying an additional 6,112 shares during the last quarter. Lansforsakringar Fondforvaltning AB publ acquired a new position in Alnylam Pharmaceuticals during the fourth quarter valued at $10,011,000. Bannerman Wealth Management Group LLC acquired a new position in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $327,000. Finally, Siemens Fonds Invest GmbH boosted its holdings in Alnylam Pharmaceuticals by 137.7% during the fourth quarter. Siemens Fonds Invest GmbH now owns 3,245 shares of the biopharmaceutical company's stock worth $764,000 after buying an additional 1,880 shares in the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.